Nuo Therapeutics has experienced a supply chain interruption in 2026 due to Pfizer's limited availability of a critical reagent, bovine thrombin, causing temporary out-of-stock situations. The company is pursuing alternative supply options. Commercial revenues increased to approximately $3.1 million in 2025, supported by a distribution agreement with Smith+Nephew. The company continues to expand its sales network and product adoption following favorable Medicare coverage.

• In early August 2026, Aurix products faced temporary out-of-stock status due to Pfizer's supply interruption of bovine thrombin, a critical reagent, with recovery expected in early 2027; the company is pursuing alternative supplies and regulatory relief [S2].
• Nuo Therapeutics recorded product revenues of approximately $3.1 million in 2025, up from $1.4 million in 2024, reflecting increased adoption following the 2021 CMS National Coverage Determination [S1].
• The company entered a Distribution Agreement with Smith+Nephew in March 2025, granting exclusive U.S. distribution rights for a private label Aurix product with minimum annual purchase commitments and upfront fees totaling $1.5 million [S1].
• As of December 31, 2025, Nuo Therapeutics had contractual relationships with over 200 third-party sales representatives to broaden commercial customer relationships [S1].
• CMS reimbursement rates for Aurix in 2026 are $2,108 per treatment in hospital outpatient departments and $1,064 per treatment in physician offices, supporting economic viability [S1].

The Aurix System addresses a significant unmet medical need in chronic wound care with clinical evidence supporting improved healing outcomes. Favorable Medicare coverage and reimbursement rates enhance economic viability and market access. The distribution agreement with Smith+Nephew expands commercial reach in the U.S. The company has grown revenues steadily since resuming operations in 2021 and has established a broad sales network. Potential exists for further adoption in physician office and hospital outpatient settings, supported by reimbursement mechanisms.

Nuo Therapeutics faces supply chain risks due to sole sourcing of a critical reagent, bovine thrombin, with recent interruptions causing product shortages. The company operates in a competitive advanced wound care market with other FDA-cleared platelet products. Commercial adoption depends on physician awareness and reimbursement administration by local Medicare contractors, which may vary. The company has reported net losses and limited financial resources, with liquidity ratios indicating moderate short-term financial flexibility. Regulatory and manufacturing challenges could impact operations and growth.

Nuo Therapeutics' moat is based on its FDA-cleared Aurix System, a unique autologous platelet rich plasma therapy for chronic wound care with demonstrated clinical efficacy supported by peer-reviewed studies. The company's favorable Medicare coverage and reimbursement rates provide economic viability in key care settings. Its exclusive distribution agreement with Smith+Nephew in the U.S. for a private label product adds commercial reach. Intellectual property protection is maintained through trademarks, trade secrets, and contractual measures. However, reliance on sole suppliers for critical reagents and the niche nature of the product limit the moat's breadth and expose the company to supply chain risks.

• Supply Chain Interruption: The company relies on Pfizer as the sole supplier of bovine thrombin (TJMI), a critical reagent for Aurix. In 2026, Pfizer experienced supply interruptions causing temporary out-of-stock situations. There is uncertainty about the timing and terms of resumption of supply, and alternative sources face regulatory and cost challenges.
• Regulatory and Reimbursement Risks: Although CMS issued a favorable National Coverage Determination in 2021, reimbursement beyond 20 weeks and in some settings depends on local Medicare Administrative Contractors. Changes in reimbursement policies or administration could affect product adoption and revenues.
• Commercial Adoption and Competition: The advanced wound care market is competitive with multiple FDA-cleared platelet products. The company must increase physician awareness and broaden commercial relationships to grow revenues. Market penetration may be limited by reimbursement complexities and competition.
• Financial and Operational Risks: The company reported net losses and has moderate liquidity with a current ratio of 1.28 as of June 30, 2026. Limited financial resources and operational scale may constrain growth and ability to manage supply chain or regulatory challenges.

• Nuo Therapeutics, Inc. is a Delaware corporation originally organized in 1998 and renamed in 2014 from Cytomedix, Inc.
• The company is a commercial-stage medical device company focused on developing and marketing products for chronic wound care primarily in the U.S.
• Its principal commercial product is the Aurix System, an FDA 510(k) cleared device since 2007 that produces autologous platelet rich plasma (PRP) gel for wound management, including chronic wounds such as diabetic ulcers, leg ulcers, and pressure ulcers.
• Aurix is one of three FDA-cleared platelet derived products for chronic wound care and can be used for most exuding wounds.
• The advanced wound care market was estimated at approximately $10.8 billion globally in 2021, with the North American market about $4.15 billion in 2020.
• Aurix therapy involves processing a small draw of the patient's peripheral blood to produce a biologically active hematogel that delivers growth factors and signaling molecules to promote wound healing.
• The company had a period of ceased operations in 2019 awaiting Medicare coverage reconsideration but restarted business activities in October 2021 after CMS issued a favorable National Coverage Determination (NCD) in April 2021 for autologous PRP products.
• CMS reimbursement rates for Aurix were $2,108 per treatment in hospital outpatient departments (POS 22) and $1,064 per treatment in physician offices (POS 11) for 2026, making the product economically viable in these settings.
• Nuo Therapeutics has established contractual relationships with over 200 third-party sales representatives as of December 31, 2025, and recorded product revenues of approximately $3.1 million in 2025, up from $1.4 million in 2024.
• The company entered a Distribution Agreement with Smith+Nephew in March 2025, granting exclusive U.S. distribution rights for a private label Aurix product with minimum annual purchase commitments averaging $500,000 per year and upfront fees totaling $1.5 million plus potential additional fees.
• Nuo Therapeutics manufactures, packages, and ships the Aurix and Private Label products to Smith+Nephew's customers under this agreement while retaining rights to market its own branded Aurix product.
• The company relies on trademarks, trade secrets, copyrights, confidentiality agreements, and contractual provisions to protect its intellectual property.
• Aurix's efficacy is supported by multiple peer-reviewed clinical studies demonstrating improved healing rates and times for chronic wounds, including diabetic foot ulcers.
• The company outsources manufacturing of Aurix components, including a critical reagent bovine thrombin (TJMI) supplied solely by Pfizer under a long-standing agreement.
• In 2026, Pfizer experienced supply interruptions of TJMI due to issues with a co-packaged diluent, causing temporary out-of-stock situations for Aurix products in early August 2026.
• Nuo Therapeutics is pursuing alternative thrombin supplies, including FDA regulatory relief, human recombinant thrombin, and international sources, but faces uncertainty regarding timing, regulatory approval, and cost.
• As of June 30, 2026, the company had $449,325 in cash and cash equivalents, current assets of $1,993,435, current liabilities of $1,554,001, a current ratio of 1.28, and a cash ratio of 0.29.
• The company reported a net loss of $277,601 for the quarter ended June 30, 2026, and basic earnings per share of -$0.01 for the same period.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.